专利号:US-9085538-B2 优先权日:2010-07-26 标题:Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof 发明人:CASAR ZDENKO; STERK DAMJAN; JUKIC MARKO 权利人:CASAR ZDENKO; STERK DAMJAN; JUKIC MARKO; LEK PHARMACEUTICALS 摘要:The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.
专利号:US-9932361-B2 优先权日:2013-02-20 标题:Convenient process for the preparation of statins 发明人:DE LUCCHI OTTORINO; TARTAGGIA STEFANO; FERRARI CLARK; GALVAGNI MARCO; PONTINI MARTA; FOGAL STEFANO; MOTTERLE RICCARDO; MORENO ROSA MARIA; COMELY ALEX 权利人:F I S —FABBRICA ITALIANA SINTETICI S P A 摘要:Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins.
专利号:US-10022366-B2 优先权日:2013-04-23 标 题:Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery 发明人:STINCHCOMB AUDRA L; GHOSH PRIYANKA 权利人:STINCHCOMB AUDRA L; GHOSH PRIYANKA; UNIV MARYLAND; UNIV KENTUCKY RES FOUND 摘要:Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.
专利号:WO-2014045294-A1 优先权日:2012-09-20 标题:A novel process for the preparation of rosuvastatin calcium using novel intermediates 发明人:KIRAN KUMAR RAMPALLY; MADHUSUDHAN GUTTA; SANKAR ARJUNAN; NAGENDER DINDIGALA; VENU KONDA; CHANDRA SHEKHAR KATKHAM 权利人:INOGENT LAB PRIVATE LTD 摘要:The present invention relates to novel process for the preparation of [(E)-7-[4-(4-fluorophenyl)-6-isopropy 1-2-isopropyl-2-[methyl (methyllsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoicacid] calcium salt using novel intermediates. Novel intermediate compounds and processes for the selective synthesis of Rosuvastatin calcium of the formula (I) using these novel intermediate compounds are disclosed. In one aspect, the present invention relates to a process for the preparation of Rosuvastatin or a pharmaceutically acceptable salt thereof of Formula I.
专利号:US-9376397-B2 优先权日:2009-02-02 标 题 :Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof 发明人:CASAR ZDENKO; KOSMRLJ JANEZ 权利人:LEK PHARMACEUTICALS 摘要:The present invention relates in general to the field of organic chemistry and in particular to the preparation of N-(4-(4-fluorophenyl)-6-isopropyl-5-methylpyrimidin-2-yl)-N-methylmethanesulfonamide (I), N-(4-(4-fluorophenyl)-5-(bromomethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (II) and N-(4-(4-fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (III), key intermediates in preparation of Rosuvastatin.
专利号:US-9067895-B2 优先权日:2009-12-16 标题 :Processes for the preparation of key intermediate for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof 发明人:ANDRENSEK SAMO; ANZEL JOLANDA; HOCEVAR MARJETA; CASAR ZDENKO 权利人:ANDRENSEK SAMO; ANZEL JOLANDA; HOCEVAR MARJETA; CASAR ZDENKO; LEK PHARMACEUTICALS 摘要:The present invention relates in general to the field of organic chemistry and in particular to a process for the preparation of 5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVL) as well as a process for preparing crystalline 5-((E)-2-((2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVLTBS) useful as key intermediates for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof.
1: Yang Y, Wu YX, Hu YZ. Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2015 Jul;94(30):e1226. doi: 10.1097/MD.0000000000001226. Review. 2: Drapkina OM, Eliashevich SO. [Efficacy and Safety of Rosuvastatin in Patients of Different Risk Groups of Developing Cardiovascular Diseases]. Kardiologiia. 2015;55(2):72-81. Review. Russian. doi: 10.1055/s-0041-100713. Epub 2015 Mar 3. Review. German. doi: 10.1002/14651858.CD010254.pub2. Review. doi: 10.1007/s40264-014-0169-4. Review. doi: 10.3810/pgm.2014.03.2736. Review. doi: 10.2147/CIA.S41356. Epub 2013 Dec 9. Review. 8: Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles. Am J Cardiol. 2014 Jan 15;113(2):292-301. doi: 10.1016/j.amjcard.2013.08.043. Epub 2013 Oct 3. Review. doi: 10.1517/17425255.2014.851667. Epub 2013 Oct 25. Review. doi: 10.1016/j.ejphar.2013.04.025. Epub 2013 May 3. Review. doi: 10.1007/s00380-013-0358-6. Epub 2013 May 5. Review. doi: 10.1517/14656566.2013.789860. Epub 2013 Apr 11. Review. doi: 10.3810/pgm.2013.01.2620. Review. Review. Russian. Review. Russian. Review. Review. Russian. Review. Japanese. doi: 10.1586/erc.11.145. Review. doi: 10.1517/14740338.2012.626764. Review.
合成参考文献
参考文献:10.2165/11531530-000000000-00000 摘要:Sawayama Y, Maeda S, Ohnishi H, Hayashi S, Hayashi J. Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study. Clin Drug Investig. 2010;30(3):157–66. doi: 10.2165/11531530-000000000-00000. 参考文献:10.1016/j.atherosclerosis.2011.06.031 摘要:Tanaka N, Abe-Dohmae S, Iwamoto N, Fitzgerald ML, Yokoyama S. HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7. Atherosclerosis. 2011 Aug;217(2):407–14. doi: 10.1016/j.atherosclerosis.2011.06.031.